How does azelaic acid help rosacea?

What it does for the bumps and redness

Azelaic acid works mainly on the papules and pustules of papulopustular rosacea, and it also helps some background redness. In two vehicle-controlled phase III gel trials with 329 and 335 patients, mean inflammatory lesion reduction was 58% versus 40% in the first and 51% versus 39% in the second (phase III gel results in JAAD00405-5/abstract)).

Erythema improved more with gel as well, at 44% versus 29% and 46% versus 28% across the two studies. Investigator global success was 61% and 62% with gel, compared with 40% and 48% with vehicle. These are real differences, but they are moderate, and roughly half of gel patients still did not reach clear or near-clear skin in these trials.

How it compares with metronidazole

The bottom line is that azelaic acid looks at least comparable to metronidazole, based on limited head-to-head data. In a randomized trial of 251 patients using 0.75% metronidazole gel twice daily for 15 weeks, 48% of azelaic acid patients reached excellent improvement or complete remission, versus 35% on metronidazole (JAMA Dermatology comparison trial).

The systematic review reached a similar conclusion, that azelaic acid appears about as effective as, if not better than, metronidazole (systematic review of RCTs). The DARE appraisal flagged that this comparison relies partly on studies outside the review, so we would hold that conclusion loosely (DARE record).

Foam, regulatory status and what patients report

FDA reviewers recommended approving 15% foam for inflammatory papules and pustules in mild-to-moderate rosacea in adults 18 and older, based on two pivotal vehicle-controlled trials (FDA review of azelaic acid foam). The gel has been labeled since 1995, according to the same review.

In a 2015 phase 3 foam trial of 961 participants over 12 weeks, IGA success was 32.0% versus 23.5% for vehicle. That figure comes from a secondary review quoting the trial, so we could not check it against the primary paper (mechanisms and clinical applications review).

Patients rated foam better overall, with 57.2% versus 44.7% reporting excellent or good results. They rated its tolerability lower, at 67.8% versus 78.2% (patient-reported outcomes of the foam trial).

What it does not do, and what is still unknown

Azelaic acid does not appear to help visible blood vessels. The systematic review found no significant effect on telangiectasia in any included study (systematic review of RCTs). If visible vessels or flushing are your main concern, this is not the tool for that job.

The real-world evidence is a small open-label study with no control group. It reported that lesion reduction persisted beyond the active treatment phase, which is encouraging but not conclusive (real-world gel study).

How it works, how it is used, and what to watch for

The proposed mechanism is anti-inflammatory, with antimicrobial and keratolytic effects. Reviews describe inhibition of the kallikrein-5 pathway and lower LL-37 levels (multiple uses review), along with reduced reactive oxygen species and cytokine activity (mechanism review). The antibacterial explanation involving thioredoxin reductase is reported in the same source, but we did not verify it in primary microbiology work.

Trial arms used 0.5 g applied twice daily for 12 weeks (ClinicalTrials.gov entry for the foam trial). Reviews describe mild, transient local irritation with 15–20% formulations (comprehensive review). Alcohol-containing or drying products may add irritation; that is our inference, not a stated finding (MedlinePlus).